We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
+56.31%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$117M
AUM Growth
+$15.6M
Cap. Flow
+$1.11M
Cap. Flow %
0.95%
Top 10 Hldgs %
40.03%
Holding
80
New
28
Increased
7
Reduced
10
Closed
27

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$3.86M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$2.6M
3
TVTX icon
Travere Therapeutics
TVTX
+$2.35M
4
MOR
MorphoSys AG American Depositary Shares
MOR
+$2.29M
5
CRBP icon
Corbus Pharmaceuticals
CRBP
+$2.17M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$5.54M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$2.78M
3
GPCR icon
Structure Therapeutics
GPCR
+$2.78M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$2.75M
5
LEGN icon
Legend Biotech
LEGN
+$2.28M

Sector Composition

Rank Sector Weight
1 Healthcare 98.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGNX icon
26
Regenxbio
RGNX
$620M
$1.78M 1.52%
+84,470
New +$1.5M
BIIB icon
27
Biogen
BIIB
$30B
$1.77M 1.51%
8,200
– –
OCUL icon
28
Ocular Therapeutix
OCUL
$1.79B
$1.76M 1.51%
+193,600
New +$1.37M
AGIO icon
29
Agios Pharmaceuticals
AGIO
$1.79B
$1.75M 1.5%
+59,902
New +$1.6M
NTRA icon
30
Natera
NTRA
$38.3B
$1.71M 1.46%
18,650
– –
PEN icon
31
Penumbra
PEN
$12.6B
$1.64M 1.41%
7,353
-1,200
-14% -$297K
GH icon
32
Guardant Health
GH
$21.5B
$1.63M 1.4%
+79,000
New +$1.69M
OLMA icon
33
Olema Pharmaceuticals
OLMA
$1B
$1.62M 1.39%
+143,400
New +$1.85M
ARWR icon
34
Arrowhead Research
ARWR
$11.9B
$1.59M 1.36%
+55,700
New +$1.78M
BBIO icon
35
BridgeBio Pharma
BBIO
$15.7B
$1.51M 1.29%
48,807
-16,306
-25% -$555K
TERN
36
DELISTED
Terns Pharmaceuticals
TERN
$1.49M 1.28%
+227,821
New +$1.49M
MRNS
37
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.47M 1.26%
+163,100
New +$1.59M
NARI
38
DELISTED
Inari Medical, Inc. Common Stock
NARI
$1.44M 1.24%
+30,100
New +$1.61M
QTRX icon
39
Quanterix
QTRX
$164M
$1.41M 1.2%
+59,650
New +$1.48M
ITCI
40
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.4M 1.2%
20,300
-8,000
-28% -$550K
SWAV
41
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$1.3M 1.12%
4,000
– –
YARW
42
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$1.28M 1.09%
8,309
+5,947
+252% +$641K
RGLS
43
DELISTED
Regulus Therapeutics
RGLS
$1.16M 0.99%
402,504
+224,100
+126% +$365K
QTTB icon
44
Q32 Bio
QTTB
$466M
$1.11M 0.95%
+65,021
New +$896K
ZLAB icon
45
Zai Lab
ZLAB
$2.06B
$1.05M 0.9%
+65,300
New +$1.38M
ELVN icon
46
Enliven Therapeutics
ELVN
$3.92B
$1.01M 0.87%
+57,635
New +$884K
VTYX
47
DELISTED
Ventyx Biosciences
VTYX
$902K 0.77%
+163,922
New +$750K
RARE icon
48
Ultragenyx Pharmaceutical
RARE
$2.45B
$831K 0.71%
+17,800
New +$840K
NBP
49
NovaBridge Biosciences American Depositary Shares
NBP
$185M
$606K 0.52%
+325,762
New +$600K
ADAG
50
Adagene
ADAG
$248M
$435K 0.37%
+155,383
New +$484K
1
2
3 4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
PA
Promethium Advisors Bethesda, Maryland $193M AUM 23.69% 1-Year Est. Return
SCPM
Sea Cliff Partners Management San Francisco, California $194M AUM 8.22% 1-Year Est. Return
CA
Carson Advisory Athens, Georgia $193M AUM 14.52% 1-Year Est. Return

Exome Asset Management's Q1 2024 Portfolio in Review

As of Q1 2024, Exome Asset Management held 80 positions worth $117M, up 15% from $101M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Exome Asset Management's Q1 2024 filing shows 28 new, 7 increased, 10 reduced and 27 closed positions. Its largest new stake was Centessa Pharmaceuticals: 274,900 shares worth $3.11M. The largest sale was Immunogen Inc, an estimated $5.54M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

  • Exome Asset Management's largest Q1 2024 buy was Centessa Pharmaceuticals: 274,900 shares worth $3.11M.
  • Exome Asset Management added most to BeOne Medicines Ltd in Q1 2024, an estimated $3.86M increase.
  • Exome Asset Management's biggest Q1 2024 reduction was Alpine Immune Sciences Inc, cutting an estimated $1.67M.
  • Exome Asset Management fully exited Immunogen Inc in Q1 2024, selling an estimated $5.54M.
  • Exome Asset Management's ten largest holdings make up 40% of its $117M portfolio in Q1 2024.
  • Exome Asset Management opened 28 new positions and closed 27 in Q1 2024.
  • Exome Asset Management's portfolio value rose 15% quarter-over-quarter to $117M.

Based on Exome Asset Management's 13F filing for Q1 2024, filed 15 May 2024.